Evidence map›Paper›PMID 38075748›Full record

ArticleACS omega2023

Tetrazine Glycoconjugate for Pretargeted Positron Emission Tomography Imaging of

Tatsiana Auchynnikava, Antti Äärelä, Heidi Liljenbäck, Juulia Järvinen, Putri Andriana, Luciana Kovacs, Jarkko Rautio, Johan Rajander, Pasi Virta, Anne Roivainen and 2 more

Open access · goldAbstract read
In one paragraph

Article in ACS omega, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Head-to-Head Comparison of theMolecular pharmaceutics · 2025
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Tatsiana AuchynnikavaTurku PET Centre, University of Turku, Turku FI-20520, Finland.
Antti ÄäreläDepartment of Chemistry, University of Turku, Turku FI-20500, Finland.
Heidi LiljenbäckTurku PET Centre, University of Turku, Turku FI-20520, Finland.
Juulia JärvinenSchool of Pharmacy, University of Eastern Finland, Kuopio FI-70210, Finland.
Putri AndrianaTurku PET Centre, University of Turku, Turku FI-20520, Finland.
Luciana KovacsTurku PET Centre, University of Turku, Turku FI-20520, Finland.
Jarkko RautioSchool of Pharmacy, University of Eastern Finland, Kuopio FI-70210, Finland.
Johan RajanderAccelerator Laboratory, Åbo Akademi University, Turku FI-20520, Finland.ORCID https://orcid.org/0000-0003-3591-0963
Pasi VirtaDepartment of Chemistry, University of Turku, Turku FI-20500, Finland.ORCID https://orcid.org/0000-0002-6218-2212
Anne RoivainenTurku PET Centre, University of Turku, Turku FI-20520, Finland.ORCID https://orcid.org/0000-0002-4006-7977
Xiang-Guo LiTurku PET Centre, University of Turku, Turku FI-20520, Finland.ORCID https://orcid.org/0000-0002-9118-7223
Anu J AiraksinenTurku PET Centre, University of Turku, Turku FI-20520, Finland.ORCID https://orcid.org/0000-0002-5943-3105
University of Turku · FIÅbo Akademi University · FIUniversity of Eastern Finland · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pretargeted concept in positron emission tomography (PET) together with bioorthogonal chemistry is an elegant solution to study processes with slow pharmacokinetics by utilizing radiotracers labeled with short-lived radionuclides. Namely, radiotracers based on tetrazine ligation with

Identifiers

PMID38075748
PMCPMC10702189
OpenAlexW4388977058

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.